MA52635A - Inhibiteurs de magl - Google Patents

Inhibiteurs de magl

Info

Publication number
MA52635A
MA52635A MA052635A MA52635A MA52635A MA 52635 A MA52635 A MA 52635A MA 052635 A MA052635 A MA 052635A MA 52635 A MA52635 A MA 52635A MA 52635 A MA52635 A MA 52635A
Authority
MA
Morocco
Prior art keywords
magl inhibitors
magl
inhibitors
Prior art date
Application number
MA052635A
Other languages
English (en)
Inventor
Daniel J Buzard
Cheryl A Grice
Michael B Shaghafi
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68534223&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA52635(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of MA52635A publication Critical patent/MA52635A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D305/06—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D305/08—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
MA052635A 2018-05-15 2019-05-14 Inhibiteurs de magl MA52635A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862671985P 2018-05-15 2018-05-15

Publications (1)

Publication Number Publication Date
MA52635A true MA52635A (fr) 2021-03-24

Family

ID=68534223

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052635A MA52635A (fr) 2018-05-15 2019-05-14 Inhibiteurs de magl

Country Status (25)

Country Link
US (3) US10570106B2 (fr)
EP (1) EP3793547A4 (fr)
JP (1) JP2021523200A (fr)
KR (1) KR20210010475A (fr)
CN (1) CN112088001A (fr)
AR (1) AR115092A1 (fr)
AU (1) AU2019271123A1 (fr)
BR (1) BR112020000863A2 (fr)
CA (1) CA3097063A1 (fr)
CL (1) CL2020002927A1 (fr)
CO (1) CO2020013550A2 (fr)
CR (1) CR20200545A (fr)
DO (1) DOP2020000207A (fr)
EA (1) EA202092586A1 (fr)
GE (1) GEP20227443B (fr)
JO (1) JOP20200276A1 (fr)
MA (1) MA52635A (fr)
MX (1) MX2020012158A (fr)
NI (1) NI202000080A (fr)
PE (1) PE20211385A1 (fr)
PH (1) PH12020551934A1 (fr)
SG (1) SG11202011228TA (fr)
TW (1) TW201946906A (fr)
WO (1) WO2019222266A1 (fr)
ZA (1) ZA202006327B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3698782B1 (fr) 2012-01-06 2024-05-15 H. Lundbeck A/S Composés carbamates pour utilisation en thérapie
JP7042804B2 (ja) 2016-09-19 2022-03-28 ルンドベック ラ ホーヤ リサーチ センター，インク． ピペラジンカルバメート、及びその製造と使用の方法
BR112020021648A2 (pt) 2018-05-14 2021-01-26 Gilead Sciences, Inc. inibidores de mcl-1
US10570106B2 (en) 2018-05-15 2020-02-25 Lundbeck La Jolla Research Center, Inc. MAGL inhibitors
EP3914589A4 (fr) * 2019-01-25 2022-11-30 H. Lundbeck A/S Méthodes de traitement d'une maladie à l'aide d'inhibiteurs de magl
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
CA3159391A1 (fr) * 2019-11-15 2021-05-20 H. Lundbeck A/S Formes cristallines d'un inhibiteur de magl
KR20220105661A (ko) 2019-11-26 2022-07-27 길리애드 사이언시즈, 인코포레이티드 Mcl1 억제제를 제조하기 위한 방법 및 중간체
JP2023523219A (ja) 2020-04-21 2023-06-02 ハー・ルンドベック・アクチエゼルスカベット モノアシルグリセロールリパーゼ阻害剤の合成
EP4198023A1 (fr) 2021-12-16 2023-06-21 Basf Se Composés de thiosemicarbazone actifs sur le plan pesticide
WO2023156402A1 (fr) 2022-02-17 2023-08-24 Basf Se Composés thiosemicarbazone à action pesticide

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1593586A (fr) 1967-10-17 1970-06-01
JPS6183073A (ja) 1984-10-01 1986-04-26 Oki Electric Ind Co Ltd 印字装置の用紙送り方法
WO1989011794A1 (fr) 1988-06-07 1989-12-14 Rikagaku Kenkyusho Inhibiteur de la croissance de plantes
EP0619804B1 (fr) 1991-11-27 1996-05-22 E.I. Du Pont De Nemours And Company Derives herbicides a base d'amino-(phenyle- ou pyridinyle- ou thienyle-)-phenyle acyles
DE69408873T2 (de) 1993-12-22 1998-07-09 Shell Int Research Verfahren zur herstellung von carbamaten
WO1997018196A1 (fr) 1995-11-15 1997-05-22 Zeneca Limited Composes herbicides a base de pyrazole substitue
WO1998000408A1 (fr) 1996-07-02 1998-01-08 Novartis Ag Derives heterocycliques n-phenylimino et leur utilisation comme herbicides
RU2167150C2 (ru) 1998-03-25 2001-05-20 Фокин Александр Васильевич Полифторалкил-n-арилкарбаматы, обладающие антимикробной активностью
CA2386540A1 (fr) 1999-10-04 2001-04-12 University Of Medicine And Dentistry Of New Jersey Noueaux carbamates et urees
EP1201298A1 (fr) 2000-10-24 2002-05-02 Urea Casale S.A. Dispositif pour la condensation de carbamate
DE10348022A1 (de) 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
FR2864080B1 (fr) 2003-12-23 2006-02-03 Sanofi Synthelabo Derives de 1-piperazine-et-1-homopiperazine-carboxylates, leur preparation et leur application en therapeutique
AU2003300702A1 (en) 2003-12-31 2005-07-21 Council Of Scientific And Industrial Research Process for preparing carbamates
KR20070026382A (ko) 2004-02-18 2007-03-08 아스트라제네카 아베 아세틸린성 피페라진 화합물 및 대사성 글루타메이트수용체 길항제로서 이들의 용도
US7786113B2 (en) 2004-12-23 2010-08-31 Hoffman-La Roche Inc. Heterocyclic carbamate derivatives, their manufacture and use as pharmaceutical agents
ME02222B (me) 2004-12-30 2016-02-20 Janssen Pharmaceutica Nv Amid derivati piperidin-i piperazin-1-karboksilne kiseline te povezani spojevi kao modulatori amid hidrolaze masnih kiselina (faah) za liječenje tjeskobe, boli i drugih stanja
JP2009514935A (ja) 2005-11-05 2009-04-09 アストラゼネカ・アクチエボラーグ 新規化合物
JP2009523729A (ja) 2006-01-13 2009-06-25 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎の治療方法
JP5442448B2 (ja) 2006-12-22 2014-03-12 アステックス、セラピューティックス、リミテッド Ｆｇｆｒインヒビターとしての二環式ヘテロ環式化合物
JP2010519337A (ja) 2007-02-26 2010-06-03 コーサン バイオサイエンシーズ， インコーポレイテッド カルバメート化合物
US8188098B2 (en) 2008-05-19 2012-05-29 Hoffmann-La Roche Inc. GPR119 receptor agonists
US20110118286A1 (en) 2008-07-16 2011-05-19 Santhosh Francis Neelamkavil Bicyclic heterocycle derivatives and their use as gpcr modulators
US8772318B2 (en) 2008-11-14 2014-07-08 The Scripps Research Institute Methods and compositions related to targeting monoacylglycerol lipase
JP2012521425A (ja) 2009-03-23 2012-09-13 Ｍｓｄ株式会社 オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体
EP2421848A1 (fr) 2009-04-22 2012-02-29 Janssen Pharmaceutica N.V. Azétidinyl diamides en tant qu'inhibiteurs de la monoacylglycérol lipase
UA107791C2 (en) 2009-05-05 2015-02-25 Dow Agrosciences Llc Pesticidal compositions
TWI506011B (zh) 2009-11-03 2015-11-01 Bayer Materialscience Ag 在光聚合物調配物中作為添加劑之氟胺基甲酸酯
FR2960875B1 (fr) 2010-06-04 2012-12-28 Sanofi Aventis Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique
EP3698782B1 (fr) 2012-01-06 2024-05-15 H. Lundbeck A/S Composés carbamates pour utilisation en thérapie
CN115536635A (zh) 2012-01-06 2022-12-30 法国施维雅药厂 治疗活性化合物及其使用方法
CA2866302A1 (fr) 2012-03-19 2013-09-26 Abide Therapeutics, Inc. Composes carbamates et leur procede de fabrication et d'utilisation
JP2014005245A (ja) 2012-06-26 2014-01-16 Dainippon Sumitomo Pharma Co Ltd 二環性ピリミジン誘導体を含有する医薬組成物
US9551036B2 (en) 2013-02-25 2017-01-24 Whitehead Institute For Biomedical Research Metabolic gene mesenchymal signatures and uses thereof
WO2015003002A1 (fr) 2013-07-03 2015-01-08 Abide Therapeutics, Inc. Composés de pyrrolo-pyrrole carbamate et composés organiques associés, compositions pharmaceutiques et leurs utilisations médicales
WO2016014975A2 (fr) 2014-07-25 2016-01-28 Northeastern University Inhibiteurs, à base d'urée/carbamates, de faah, de magl ou des deux à la fois (faah/magl) et leurs utilisations
CA2979537C (fr) 2015-03-18 2023-08-29 Abide Therapeutics, Inc. Carbamates de piperazine et procedes de preparation et d'utilisation de ceux-ci
JP7042804B2 (ja) 2016-09-19 2022-03-28 ルンドベック ラ ホーヤ リサーチ センター，インク． ピペラジンカルバメート、及びその製造と使用の方法
SI3541807T1 (sl) 2016-11-16 2022-01-31 H. Lundbeck A/S Kristalinična oblika zaviralca MAGL
JOP20190105A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
EA202090296A1 (ru) 2017-08-29 2020-08-03 Лундбекк Ла-Хойя Рисерч Сентер, Инк. Спироциклические соединения и способы их получения и применения
US10570106B2 (en) 2018-05-15 2020-02-25 Lundbeck La Jolla Research Center, Inc. MAGL inhibitors
EP3914589A4 (fr) 2019-01-25 2022-11-30 H. Lundbeck A/S Méthodes de traitement d'une maladie à l'aide d'inhibiteurs de magl

Also Published As

Publication number Publication date
CR20200545A (es) 2020-12-17
US20190352273A1 (en) 2019-11-21
PH12020551934A1 (en) 2021-06-21
NI202000080A (es) 2021-02-15
EP3793547A4 (fr) 2021-11-17
US11332453B2 (en) 2022-05-17
JOP20200276A1 (ar) 2020-11-02
EP3793547A1 (fr) 2021-03-24
JP2021523200A (ja) 2021-09-02
PE20211385A1 (es) 2021-07-27
US11214557B2 (en) 2022-01-04
MX2020012158A (es) 2021-01-29
CN112088001A (zh) 2020-12-15
WO2019222266A1 (fr) 2019-11-21
US10570106B2 (en) 2020-02-25
TW201946906A (zh) 2019-12-16
CA3097063A1 (fr) 2019-11-21
ZA202006327B (en) 2022-06-29
CL2020002927A1 (es) 2021-03-05
US20200148653A1 (en) 2020-05-14
GEP20227443B (en) 2022-11-25
CO2020013550A2 (es) 2020-11-10
EA202092586A1 (ru) 2021-03-10
AR115092A1 (es) 2020-11-25
DOP2020000207A (es) 2021-02-15
SG11202011228TA (en) 2020-12-30
AU2019271123A1 (en) 2020-11-26
BR112020000863A2 (pt) 2020-12-08
US20210206735A1 (en) 2021-07-08
KR20210010475A (ko) 2021-01-27

Similar Documents

Publication Publication Date Title
MA54543A (fr) Inhibiteurs de kif18a
MA54550A (fr) Inhibiteurs de kif18a
MA52635A (fr) Inhibiteurs de magl
MA46857A (fr) Inhibiteurs de magl
MA52812A (fr) Inhibiteurs de sarm1
MA46860A (fr) Inhibiteurs de magl
MA46855A (fr) Inhibiteurs de magl
MA53287A (fr) Inhibiteurs de prmt5
MA50406A (fr) Inhibiteurs pyrazole de magl
MA51611A (fr) Inhibiteurs de pi4kiiibêta
MA52809A (fr) Inhibiteurs de sarm1
MA52813A (fr) Inhibiteurs de sarm1
DK3752258T3 (da) Trampolin
DK3587968T3 (da) Fluidsystem
MA49925A (fr) Claie
DE112019000442A5 (de) Ringtilgereinrichtung
NO20181678A1 (no) Rissanviser
JP1628556S (ja) たい焼
JP1628555S (ja) たい焼
ES1218724Y (es) Terrario
ES1224156Y (es) Ecobolsera
UA38411S (uk) Термокухоль
UA38582S (uk) Термокухоль
UA38581S (uk) Термокухоль
MA47730A (fr) Inhibiteurs de bêta-sécrétase